Literature DB >> 17547510

Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches.

Jacqueline M Achkar1, Arturo Casadevall, Aharona Glatman-Freedman.   

Abstract

The emergence of multidrug-resistant tuberculosis strains and the coinfection with HIV, together with advances in immunology, have led to renewed interest regarding ways to exploit the immune responses against Mycobacterium tuberculosis therapeutically. Here we review the fundamentals of tuberculosis therapy in view of the epidemiological and clinical challenges, and explore the experience with immune-based therapies for the treatment of active tuberculosis. These immune-based therapies are discussed here with the aim of assessing their potential use as adjuncts to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547510     DOI: 10.1586/14787210.5.3.461

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  4 in total

1.  Correlation between serum and plasma antibody titers to mycobacterial antigens.

Authors:  Michael Siev; Xian Yu; Rafael Prados-Rosales; Frank T Martiniuk; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 2.  Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.

Authors:  Jacqueline M Achkar; Elizabeth R Jenny-Avital
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

3.  Independent association of younger age with hemoptysis in adults with pulmonary tuberculosis.

Authors:  J M Achkar; G Joseph
Journal:  Int J Tuberc Lung Dis       Date:  2012-05-07       Impact factor: 2.373

4.  Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients.

Authors:  Lyudmila G Nikolaeva; Tatyana V Maystat; Lilia A Masyuk; Volodymyr S Pylypchuk; Yuri L Volyanskii; Galyna A Kutsyna
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.